NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company’s product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer’s disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Metrics to compare | NXTC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNXTCPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.3x | −3.5x | −0.5x | |
PEG Ratio | −0.01 | −0.01 | 0.00 | |
Price/Book | 0.2x | 2.6x | 2.6x | |
Price / LTM Sales | - | 161.8x | 3.3x | |
Upside (Analyst Target) | 390.4% | 178.1% | 42.8% | |
Fair Value Upside | Unlock | −1.3% | 6.5% | Unlock |